F-star Therapeutics Net Income

As of the most recent data (September 2022), FSTX shows a net income of $-45M. That compares with $-45M in the prior-year period — down 0.3% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FSTX's net income is now $-45M (was $-45M) — a 0.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether F-star Therapeutics is outperforming or lagging.

The Healthcare sector average net income is about $16B. F-star Therapeutics is at $-45M, which is lower that average. That is roughly 100.3% below the sector mean. Use the comparison chart on this page to see how FSTX stacks up against individual peers as well.

Tracking FSTX's net income over time shows whether F-star Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-45M That compares with $-45M in the prior-year period — down 0.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has F-star Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-45M) with ownership activity and broader fundamentals.